Financial Performance - Revenue for the six months ended June 30, 2024, reached RMB 2,540.4 million, representing a 58.2% increase compared to RMB 1,605.7 million in the same period of 2023[2] - Gross profit for the same period was RMB 2,093.2 million, up 54.9% from RMB 1,351.0 million year-over-year[2] - Net profit attributable to shareholders was RMB 983.2 million, reflecting a 47.4% increase from RMB 666.9 million in the prior year[2] - Adjusted net profit (non-IFRS measure) for the period was RMB 1,026.6 million, a 51.8% increase compared to RMB 676.4 million in 2023[2] - Basic earnings per share increased to RMB 0.99, up 47.8% from RMB 0.67 in the previous year[4] - The total comprehensive income for the period was RMB 982.1 million, compared to RMB 666.0 million in the same period last year[4] - The company reported a pre-tax profit of RMB 1,155.2 million, which is a 49.0% increase from RMB 775.6 million in 2023[3] - The total tax expense for the period amounted to RMB 174.64 million, compared to RMB 109.56 million in the previous year[24] - Profit for the six months ended June 30, 2024, was RMB 980.6 million, representing a 47.2% increase from RMB 666.0 million for the same period in 2023[88] Assets and Liabilities - Non-current assets increased to RMB 1,092,431 thousand as of June 30, 2024, compared to RMB 837,999 thousand as of December 31, 2023, reflecting a growth of 30.4%[6] - Current assets rose significantly to RMB 6,688,210 thousand, up from RMB 4,135,079 thousand, marking an increase of 61.8%[6] - Total liabilities increased to RMB 1,805,793 thousand, up from RMB 1,061,228 thousand, indicating a rise of 70.0%[7] - The net asset value reached RMB 5,974,848 thousand, compared to RMB 4,371,050 thousand, showing an increase of 36.7%[7] - The company’s total equity increased to RMB 5,974,848 thousand, compared to RMB 4,371,050 thousand, indicating a growth of 36.7%[7] - The company’s non-current liabilities decreased to RMB 50,146 thousand from RMB 71,416 thousand, a reduction of 29.8%[7] Revenue Sources - Customer contract revenue for the six months ended June 30, 2024, was RMB 2,540,432 thousand, representing a 58% increase from RMB 1,605,698 thousand in the same period of 2023[17] - Revenue from professional skin care products reached RMB 1,939.6 million, accounting for 76.4% of total revenue, up from 74.5% in the previous year[63] - Revenue from health food and other products was RMB 8.6 million, representing 0.3% of total revenue, down from 0.7% in the previous year[63] - Revenue from the Kewemi brand was RMB 2,070.9 million, a 68.6% increase year-over-year, accounting for 81.5% of total revenue[73] - Revenue from the Keli Jin brand was RMB 396.1 million, a 23.6% increase year-over-year, representing 15.6% of total revenue[75] Expenses - Sales and distribution expenses for the period were RMB 892.0 million, compared to RMB 555.2 million in the previous year[3] - Research and development expenses for the period were RMB 1,338.0 million, reflecting the company's commitment to innovation[3] - The group reported a significant increase in employee benefits expenses, including salaries and wages, which rose to RMB 81,757 thousand from RMB 51,819 thousand in the previous year[21] - Administrative expenses for the six months ended June 30, 2024, were RMB 65.7 million, an increase of 38.3% compared to RMB 47.5 million for the same period in 2023, primarily due to increased employee compensation from a rise in management personnel[85] - Total sales cost for the six months ended June 30, 2024, was RMB 447.2 million, a 75.6% increase from RMB 254.7 million in the same period of 2023[78] Market Strategy and Development - The company plans to continue expanding its market presence and investing in new product development to sustain growth[2] - The company continues to focus on R&D for new technologies and products, aiming to expand its market presence and optimize channel operations[36] - The company is focused on developing a comprehensive skincare solution with a series of new products set to launch in the coming months[44] - The company has launched a new "Focus Series" targeting skin conditions caused by lifestyle factors, with the first product achieving top rankings in e-commerce during promotional events[44] - The company continues to enhance its product matrix and expand its market presence through innovative marketing strategies and new product launches[40] Corporate Governance and Compliance - The company has committed to high standards of corporate governance, adhering to all applicable codes except for a deviation regarding the separation of the roles of Chairman and CEO[109][111] - The company has confirmed compliance with the standard code for securities trading by all directors during the reporting period[112] - The company has not engaged in any purchase, sale, or redemption of its listed securities during the reporting period[108] Social Responsibility - The company actively participates in social responsibility initiatives, donating over RMB 5 million in products to support education workers and medical personnel[58] - The company initiated a bottle recycling program to advocate for sustainable development and engage consumers in environmental protection[50] Future Plans and Investments - The company plans to enhance R&D efforts and expand product offerings in the second half of 2024, focusing on new products and marketing strategies[61] - There are no significant future plans for major investments or acquisitions as of June 30, 2024[95]
巨子生物(02367) - 2024 - 中期业绩